Table 1.
Baseline patient characteristics in training and validation cohort.
| Characteristics | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| BA-active (n = 41) |
BA-inactive (n = 37) |
p-value | BA-active (n = 28) |
BA-inactive (n = 25) |
p-value | |
| Age | 0.862 | 0.823 | ||||
| ≤50 years | 36 | 32 | 22 | 19 | ||
| >50 years | 5 | 5 | 6 | 6 | ||
| Sex | 0.764 | 0.232 | ||||
| Male | 18 | 15 | 10 | 13 | ||
| Female | 23 | 22 | 18 | 12 | ||
| Smoking | 0.274 | 0.487 | ||||
| No | 16 | 19 | 13 | 14 | ||
| Yes | 25 | 18 | 15 | 11 | ||
| Calcification type | <0.001 | <0.001 | ||||
| I | 2 | 13 | 1 | 12 | ||
| II | 23 | 20 | 15 | 11 | ||
| III | 16 | 4 | 12 | 2 | ||
| WBC | 0.848 | 0.883 | ||||
| ≤9.5×109/L | 36 | 33 | 25 | 22 | ||
| >9.5×109/L | 5 | 4 | 3 | 3 | ||
| NE | 0.561 | 0.122 | ||||
| ≤6.3×109/L | 39 | 34 | 27 | 21 | ||
| >6.3×109/L | 2 | 3 | 1 | 4 | ||
| LY | 0.368 | 0.486 | ||||
| ≤3.2×109/L | 35 | 34 | 27 | 23 | ||
| >3.2×109/L | 6 | 3 | 1 | 2 | ||
| Fib | <0.001 | <0.001 | ||||
| ≤4 g/L | 39 | 14 | 23 | 3 | ||
| >4 g/L | 2 | 23 | 5 | 22 | ||
| PLT | 0.731 | 0.471 | ||||
| ≤350 g/L | 38 | 35 | 24 | 23 | ||
| >350 g/L | 3 | 2 | 4 | 2 | ||
| Crea | 0.116 | 0.340 | ||||
| ≤110 µmol/L | 36 | 36 | 27 | 25 | ||
| >110 µmol/L | 5 | 1 | 1 | 0 | ||
| TBIL | 0.070 | 0.205 | ||||
| ≤22 µmol/L | 27 | 31 | 18 | 20 | ||
| >22 µmol/L | 14 | 6 | 10 | 5 | ||
| AST | 0.220 | 0.275 | ||||
| ≤59 U/L | 27 | 29 | 20 | 21 | ||
| >59 U/L | 14 | 8 | 8 | 4 | ||
| ALT | 0.092 | 0.552 | ||||
| ≤72 U/L | 29 | 32 | 23 | 22 | ||
| >72 U/L | 12 | 5 | 5 | 3 | ||
| PT | 0.560 | 0.805 | ||||
| ≤38 s | 27 | 22 | 17 | 16 | ||
| >38 s | 14 | 15 | 11 | 9 | ||
BA, bioactivity; WBC, white blood cells; NE, neutrophils count; LY, lymphocyte count; Fib, fibrinogen; PLT, platelet count; Crea, creatinine; TBIL, total bilirubin; ASL, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time.